CDC data show that antibacterial resistance has been increasing dramatically over the past few decades. Resistance is most pronounced in the hospital setting, where heavy use of antibiotics creates an ideal environment for the development of drug resistance. Approximately 70% of nosocomial, or hospital-based infections, are now resistant to at least one antibiotic.

Historically, the pharmaceutical industry was able to keep pace with the need for new antibacterial drugs. However, since 1968, only two new classes of antibacterials have been brought to market, and unfortunately, these treatments face one or more of the following limitations: limited potency, lack of a bactericidal (bacteria-killing) mechanism of action, narrow spectrum of activity, the need for intravenous or injectable administration and adverse side effects.

Achillion is advancing ACH-702, an internally discovered compound, for the treatment of serious nosocomial bacterial infections. ACH-702 has a novel target profile against bacterial DNA replication enzymes and potent broad-spectrum bactericidal activity, characteristics that indicate it may play an important role in the fight against drug-resistant bacteria.

Program Overview
Pre clinical study data indicate that ACH-702 may provide clinical benefits due to its broad spectrum of activity, bactericidal mechanism of action and oral bioavailability. more

Data Overview
ACH-702 has demonstrated acceptable pharmacokinetic and safety profiles, along with potent antibacterial activity against both sensitive and drug-resistant strains. more